Voxzogo

<p>Voxzogo is a medicine for treating achondroplasia in patients aged 4 months and older whose bones are still growing.</p><p>Achondroplasia is an inherited disease caused by a mutation (change) in a gene called fibroblast growth-factor receptor 3 (<em>FGFR3</em>). The mutation affects growth of almost all bones in the body including the skull, spine, arms and legs, resulting in very short stature with a characteristic appearance.</p><p>Achondroplasia is rare, and Voxzogo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 24 January 2013. Further information on the orphan designation can be found here: <a href="https://beta.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1094">ema.europa.eu/medicines/human/orphan-designations/EU3121094</a>.</p><p>Voxzogo contains the active substance vosoritide.</p>